Cargando…

Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits

Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH, it shows poor aqueous solubility, which leads to poor bioavailability and lowers its therapeutic effectiveness. The main aim of this research was to develop a direct compressed effervescent floating...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahamathulla, Mohamed, Saisivam, Srinivasan, Alshetaili, Abdullah, Hani, Umme, Gangadharappa, Hosahalli Veerabhadrappa, Alshehri, Sultan, Ghoneim, Mohammed M., Shakeel, Faiyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538939/
https://www.ncbi.nlm.nih.gov/pubmed/34685235
http://dx.doi.org/10.3390/polym13203476
_version_ 1784588626145837056
author Rahamathulla, Mohamed
Saisivam, Srinivasan
Alshetaili, Abdullah
Hani, Umme
Gangadharappa, Hosahalli Veerabhadrappa
Alshehri, Sultan
Ghoneim, Mohammed M.
Shakeel, Faiyaz
author_facet Rahamathulla, Mohamed
Saisivam, Srinivasan
Alshetaili, Abdullah
Hani, Umme
Gangadharappa, Hosahalli Veerabhadrappa
Alshehri, Sultan
Ghoneim, Mohammed M.
Shakeel, Faiyaz
author_sort Rahamathulla, Mohamed
collection PubMed
description Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH, it shows poor aqueous solubility, which leads to poor bioavailability and lowers its therapeutic effectiveness. The main aim of this research was to develop a direct compressed effervescent floating matrix tablet (EFMT) of LP using hydroxyl propyl methylcellulose 90SH 15,000 (HPMC-90SH 15,000), karaya gum (KG), and an effervescent agent, such as sodium bicarbonate (SB). Therefore, an EFMT has been developed to prolong the stomach residence time (GRT) of a drug to several hours and improve its bioavailability in the stomach region. The blended powder was evaluated for pre-compression characteristics, followed by post-compression characteristics, in vitro floating, water uptake studies, and in vitro studies. The optimized formulation of EFMT was investigated for in vivo buoyancy by X-ray imaging and pharmacokinetic studies in Albino rabbits. The results revealed that the parameters of pre- and post-compression were within the USP limits. All tablets showed good floating capabilities (short floating lag time <1 min and floated for >24 h), good swelling characteristics, and controlled release for over 24 h. The Fourier-transform infrared (FTIR) and differential scanning calorimetry (DSC) spectra showed drug–polymer compatibility. The optimized formulation F3 (HPMC-90SH 15,000-KG) exhibited non-Fickian diffusion and showed 100% drug release at the end of 24 h. In addition, with the optimized formulation F3, we observed that the EFMT floated continuously in the rabbit’s stomach area; thus, the GRT could be extended to more than 12 h. The pharmacokinetic profiling in Albino rabbits revealed that the relative bioavailability of the optimized LP-EFMT was enhanced compared to an oral solution of LP. We conclude that this a potential method for improving the oral bioavailability of LP to treat hypertension effectively.
format Online
Article
Text
id pubmed-8538939
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85389392021-10-24 Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits Rahamathulla, Mohamed Saisivam, Srinivasan Alshetaili, Abdullah Hani, Umme Gangadharappa, Hosahalli Veerabhadrappa Alshehri, Sultan Ghoneim, Mohammed M. Shakeel, Faiyaz Polymers (Basel) Article Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH, it shows poor aqueous solubility, which leads to poor bioavailability and lowers its therapeutic effectiveness. The main aim of this research was to develop a direct compressed effervescent floating matrix tablet (EFMT) of LP using hydroxyl propyl methylcellulose 90SH 15,000 (HPMC-90SH 15,000), karaya gum (KG), and an effervescent agent, such as sodium bicarbonate (SB). Therefore, an EFMT has been developed to prolong the stomach residence time (GRT) of a drug to several hours and improve its bioavailability in the stomach region. The blended powder was evaluated for pre-compression characteristics, followed by post-compression characteristics, in vitro floating, water uptake studies, and in vitro studies. The optimized formulation of EFMT was investigated for in vivo buoyancy by X-ray imaging and pharmacokinetic studies in Albino rabbits. The results revealed that the parameters of pre- and post-compression were within the USP limits. All tablets showed good floating capabilities (short floating lag time <1 min and floated for >24 h), good swelling characteristics, and controlled release for over 24 h. The Fourier-transform infrared (FTIR) and differential scanning calorimetry (DSC) spectra showed drug–polymer compatibility. The optimized formulation F3 (HPMC-90SH 15,000-KG) exhibited non-Fickian diffusion and showed 100% drug release at the end of 24 h. In addition, with the optimized formulation F3, we observed that the EFMT floated continuously in the rabbit’s stomach area; thus, the GRT could be extended to more than 12 h. The pharmacokinetic profiling in Albino rabbits revealed that the relative bioavailability of the optimized LP-EFMT was enhanced compared to an oral solution of LP. We conclude that this a potential method for improving the oral bioavailability of LP to treat hypertension effectively. MDPI 2021-10-10 /pmc/articles/PMC8538939/ /pubmed/34685235 http://dx.doi.org/10.3390/polym13203476 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rahamathulla, Mohamed
Saisivam, Srinivasan
Alshetaili, Abdullah
Hani, Umme
Gangadharappa, Hosahalli Veerabhadrappa
Alshehri, Sultan
Ghoneim, Mohammed M.
Shakeel, Faiyaz
Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title_full Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title_fullStr Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title_full_unstemmed Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title_short Design and Evaluation of Losartan Potassium Effervescent Floating Matrix Tablets: In Vivo X-ray Imaging and Pharmacokinetic Studies in Albino Rabbits
title_sort design and evaluation of losartan potassium effervescent floating matrix tablets: in vivo x-ray imaging and pharmacokinetic studies in albino rabbits
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538939/
https://www.ncbi.nlm.nih.gov/pubmed/34685235
http://dx.doi.org/10.3390/polym13203476
work_keys_str_mv AT rahamathullamohamed designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT saisivamsrinivasan designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT alshetailiabdullah designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT haniumme designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT gangadharappahosahalliveerabhadrappa designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT alshehrisultan designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT ghoneimmohammedm designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits
AT shakeelfaiyaz designandevaluationoflosartanpotassiumeffervescentfloatingmatrixtabletsinvivoxrayimagingandpharmacokineticstudiesinalbinorabbits